CD70 Antibodies Half-Life Optimization RCC Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for advanced Renal Cell Carcinoma (RCC), particularly those targeting VEGF, face challenges with long-term drug resistance and require more effective and safer antibody therapies that can specifically target CD70, a protein expressed on RCC cells, with improved half-life and reduced non-specific cytokine release.
Innovation Solution
Development of CD70-specific antibodies, including monospecific and bispecific formats, with optimized variable regions and modifications to enhance half-life and minimize Fc-interaction, allowing for targeted therapy with reduced immune cell activation and cytokine release.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If CD70 bispecific antibody in small molecular weight format is used, then the antibody can engage T-cells and target CD70, but the half-life is short requiring continuous infusion
Solution Approach 1:
The patent changes the molecular weight parameter by transitioning from small molecular weight bispecific formats to full-length IgG format antibodies, which naturally possess longer half-life characteristics. This parameter change resolves the contradiction by providing sustained activity without requiring continuous infusion.
2Object-affected harmful factors
If conventional antibody therapies are used, then treatment can be administered, but non-specific cytokine release and immune cell activation occur causing side effects
Solution Approach 1:
The patent applies local quality by engineering the antibody to have different functional properties in different regions: the variable regions are designed for highly specific CD70 binding, while the Fc regions are modified to minimize non-specific interactions with immune cells. This localized functional differentiation reduces harmful cytokine release while maintaining therapeutic efficacy.
Solution Approach 2:
The patent converts the potential harm of Fc-mediated immune activation into a benefit by carefully controlling Fc-interaction properties. The modified Fc regions minimize unwanted cytokine release while preserving necessary effector functions, transforming a source of side effects into a controlled therapeutic mechanism.
3Reliability
If VEGF-targeted therapies are used, then overall survival is improved, but long-term drug resistance develops leading to disease relapse
Solution Approach 1:
The patent inverts the therapeutic approach by switching from VEGF pathway inhibition to direct CD70 targeting on tumor cells. This strategic inversion bypasses the resistance mechanisms that develop against VEGF inhibitors, providing an alternative pathway for achieving sustained therapeutic response.
4Duration of action of moving object
If full-length bispecific antibody format is used, then half-life is prolonged and Fc-interaction is minimized, but manufacturing complexity increases
Solution Approach 1:
The patent employs segmentation by separately optimizing the variable regions for CD70 binding specificity and the Fc regions for minimized interaction. This modular approach allows independent characterization and manufacturing optimization of each domain, reducing overall manufacturing complexity despite the full-length format.
Data Source
AI summary
The present invention provides antibodies that specifically bind to CD70 (Cluster of Differentiation 70). The invention further provides bispecific antibodies that bind to CD70 and another antigen (e.g., CD3). The invention further relates to antibody encoding nucleic acids, and methods of obtaining such antibodies (monospecific and bispecific). The invention further relates to therapeutic methods for use of these antibodies for the treatment of CD70-mediated pathologies, including cancer.